undamentalytics Newsletter
Sign in

Valion Bio, Inc. (VBIO) stock

Add to watchlist

Add holding +

NASDAQ: VBIO Nasdaq Biotechnology

Valion Bio, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders2 buying, 0 selling2 purchases and 0 sales by directors and officers, last 12 monthsInsider trades
  • Funds7 adding, 4 cuttingOf 1 active managers that changed their stake, 1 added; quarter to June 30, 2026Fund buyers and sellers

The Fundamentalytics view

Current signal Results well ahead of expectations: Reported earnings per share beat the analysts' consensus estimate by 79% in the quarter to 2023-09-30, the 3rd beat in the last four quarters.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

Nothing in Valion Bio, Inc.'s latest figures clears our strength thresholds.

Things to watch

  • Volatile shares. Over the past year the shares showed annualised volatility of 135% and a beta of 1.4 against the S&P 500.
  • Short interest rising. Shares sold short rose 201% in a month to 5.5% of tradable shares.

Latest results

Earnings per share
-$25.16 against an average estimate of -$119.00: beat by 78.9%
Share reaction
-9.1% in the first session after the results on May 14, 2026, against -0.4% for the S&P 500

Valion Bio's figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-3.5%
  • 1 week-36.8%
  • 1 month-79.5%
  • This year-98.5%
  • 1 year-99.2%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Earnings

Last results
May 14, 2026

News & updates

Updated November 3, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Leadership
  2. Announcement
  3. Agreement
  4. Announcement
  5. Announcement
  6. Announcement
  7. Announcement
  8. Agreement
  9. Announcement
  10. Announcement
  11. Leadership
  12. Leadership

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Valion Bio, Inc. valuation models and calculator

No model value for Valion Bio, Inc. at the moment. Current status: limited reported history: available models are shown without a Buy/Hold/Sell rating. Available reported financials are shown below.

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: limited reported history: available models are shown without a Buy/Hold/Sell rating.

Valuation models

We value Valion Bio, Inc. as an operating company, with every model that fits that kind of business. Cost of equity 8.2%: the 10-year Treasury yield (4.9%) plus a beta of 0.72 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: no twelve-month earnings or share count in the filings yet
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: no twelve-month earnings or share count in the filings yet
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: no twelve-month earnings or share count in the filings yet
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. — Does not apply: revenue and margins don't support a positive value
Price-to-sales vs peers Sales per share times peers' typical price-to-sales; used only when earnings are negative. — Does not apply: no twelve-month earnings or share count in the filings yet
Combined value Weighted average of the models that apply: the primary model (price-to-earnings vs peers) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. — No model applies: the filings don’t yet support a value.

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Valion Bio, Inc. with Biotechnology in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Analysts' consensus

No analyst estimates are published for Valion Bio, Inc.: too few analysts cover it.

Earnings against estimates

Quarter toEstimateActualSurprise
Sept 2023 −$119.00 −$25.16 +78.9%
Jun 2023 −$136.00 −$119.00 +12.5%
Mar 2023 −$187.00 −$187.00 0.0%
Dec 2022 −$527.00 −$391.00 +25.8%

Adjusted EPS as companies report it, against the average analyst estimate.

Positioning

Short interest
5.5%
of tradable shares
Days to cover
0.03
at average volume
Short interest, 1 month
+201%
to October 15, 2026
Held by institutions
5%
of shares
Held by insiders
0.3%
of shares
Employees
52
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Recent prices are available. Older price history and the statistics that need it are being loaded in the background.

Return and risk by year

Calendar year 20222023202420252026 to date
Return
VBIO−84%−97%−81%−75%−99%
Industry peers (median)−56%−17%−28%−5%−26%
S&P 500−18%+26%+25%+18%+11%
Months that ended higher
VBIO42%17%33%25%18%
S&P 50042%67%75%75%46%
Largest fall from a high during the year
VBIO−85%−99%−89%−89%−99%
S&P 500−25%−10%−8%−19%−9%

Worst fall since November 11, 2021: 100% from November 16, 2021 to November 2, 2026. Getting back needed a 44660917% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$0.53 – $66.50
From 52-week high
−99.2%
vs 50-day average
−75.6%
vs 200-day average
−96.4%
Volatility (1 year)
135%
Beta vs S&P 500
1.39

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
1 up, 11 down
typical move ±10.4%
After a week
3 up, 9 down
typical move ±16.9%
After a month
2 up, 10 down
typical move ±31.1%
Results releasedNext dayS&P 500 next day5 days21 days
May 14, 2026 −9.1% −0.4% −9.2% −42.3%
March 25, 2026 −3.0% −1.2% −1.0% +30.4%
November 14, 2025 −27.7% −0.9% −20.7% −3.8%
August 14, 2025 +8.0% −0.2% −8.8% −13.4%
May 15, 2025 −1.2% +1.1% −2.1% −13.2%
March 21, 2025 −0.6% +1.8% −18.1% +107.9%
November 14, 2024 −12.4% −1.9% −26.9% −34.1%
August 14, 2024 −12.4% +2.0% +2.7% −13.6%
March 25, 2024 −12.4% −0.5% −13.1% −19.0%
November 14, 2023 −12.1% +2.2% +7.0% −15.0%
August 14, 2023 0.0% −0.6% +59.5% −32.4%
May 15, 2023 −26.4% −0.3% −34.3% −47.8%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Fundamentals

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms . Generated November 3, 2026. Definitions in our methodology.

Who owns it

Funds buying and selling
Reported value
$205,604
Institutions reporting
13
Shares held vs prior quarter
▲ 50.7%
Positions opened / closed
5 / 1

Top buyers and sellers, Q2 2026: 7 institutions bought and 4 sold ; the biggest buyer was Murchinson Ltd (+115K shares) and the biggest seller Geode Capital Management, LLC (−68K). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Murchinson Ltd. $59,789 115K 29.1% New
Citadel Advisors LLC $38,548 74K 18.7% New
Sanctuary Advisors, LLC $31,820 61K 15.5% 0.0%
Marex Group Ltd $28,224 54K 13.7% ▼ 8.4%
Virtu Financial LLC $20,000 39K 9.7% New
Geode Capital Management, LLC $10,071 19K 4.9% ▼ 77.9%
UBS Group AG $5,769 11K 2.8% ▲ 368.9%
Two Sigma Securities, LLC $5,283 10K 2.6% New
HRT Financial LP $5,000 11K 2.4% ▼ 73.0%
Tower Research Capital LLC (TRC) $1,089 2K 0.5% ▲ 258.7%
Sbi Securities Co., Ltd. $8 0K 0.0% 0.0%
TD Waterhouse Canada Inc. $2 0K 0.0% New

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Valion Bio, Inc.'s complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $28,450 2 trades by 2 insiders, last 12 months Insider sales History → $0 0 trades by 0 insiders
Net ▲ $28,450 net buying
Insider Date Trade Shares Price Value
Bolton Sheryle Director April 15, 2026 Buy 10,000 $1.04 $10,400
Valauri Christina Rizopoulos Director April 1, 2026 Buy 19,000 $0.95 $18,050

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around August 13, 2026 estimated from the company's past filing pattern, not announced

  • May 14, 2026
  • March 25, 2026
  • November 14, 2025
  • August 14, 2025
  • May 15, 2025
  • March 21, 2025

Recent SEC filings

Data status

When each part of this page on Valion Bio, Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Valion Bio, Inc. in brief

What does Valion Bio, Inc. do?
Valion Bio, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
What is Valion Bio, Inc.'s stock ticker?
Valion Bio, Inc. trades under the ticker VBIO on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
Who are Valion Bio, Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Murchinson Ltd., Citadel Advisors LLC and Sanctuary Advisors, LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
Are insiders buying or selling Valion Bio, Inc. stock?
Over the last 12 months, Valion Bio, Inc.'s directors and officers reported 2 open-market purchases and 0 sales on Form 4. The insider trading page charts every trade.